- Home
- COPL vs CERS Comparison
COPL vs CERS Comparison
Compare COPL & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COPL
- CERS
- Stock Information
- Founded
- COPL 2024
- CERS 1991
- Country
- COPL Hong Kong
- CERS United States
- Employees
- COPL N/A
- CERS N/A
- Industry
- COPL
- CERS EDP Services
- Sector
- COPL
- CERS Technology
- Exchange
- COPL NYSE
- CERS Nasdaq
- Market Cap
- COPL 238.0M
- CERS 271.4M
- IPO Year
- COPL 2025
- CERS 1997
- Fundamental
- Price
- COPL $10.03
- CERS $1.34
- Analyst Decision
- COPL
- CERS Strong Buy
- Analyst Count
- COPL 0
- CERS 2
- Target Price
- COPL N/A
- CERS $3.50
- AVG Volume (30 Days)
- COPL 92.0K
- CERS 1.4M
- Earning Date
- COPL 01-01-0001
- CERS 07-31-2025
- Dividend Yield
- COPL N/A
- CERS N/A
- EPS Growth
- COPL N/A
- CERS N/A
- EPS
- COPL N/A
- CERS N/A
- Revenue
- COPL N/A
- CERS $185,144,000.00
- Revenue This Year
- COPL N/A
- CERS $24.95
- Revenue Next Year
- COPL N/A
- CERS $8.48
- P/E Ratio
- COPL N/A
- CERS N/A
- Revenue Growth
- COPL N/A
- CERS 13.06
- 52 Week Low
- COPL $10.00
- CERS $1.12
- 52 Week High
- COPL $10.12
- CERS $2.54
- Technical
- Relative Strength Index (RSI)
- COPL N/A
- CERS 48.75
- Support Level
- COPL N/A
- CERS $1.29
- Resistance Level
- COPL N/A
- CERS $1.41
- Average True Range (ATR)
- COPL 0.00
- CERS 0.10
- MACD
- COPL 0.00
- CERS -0.01
- Stochastic Oscillator
- COPL 0.00
- CERS 27.27
About COPL COPLEY ACQUISITION CORP
Copley Acquisition Corp is a blank check company.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.